Letrozole and other aromatase inhibitors are increasingly recognized as first-line ovulation induction (OI) medications, offering an efficient and physiologic approach to ovarian stimulation that enhances outcomes in reproductive medicine. By …
Endometriosis is one of the main reproductive issues that the modifiable risk factors is still the main research focus. It is still unclear how various adiposity affect the onset and …
The human microbiota is increasingly recognized as a key component of women's reproductive health. This narrative review examines the vaginal, endometrial, and gut microbiota and their roles in the pathogenesis …
Eli Lilly Builds $1.5 Billion Stockpile of Oral GLP-1 Drug as Study Shows 66% Drop in Endometrial Cancer Risk for Certain Patients geneonline.com
Study Finds GLP-1 Medications Combined with Progestin Therapy May Lower Endometrial Cancer Risk geneonline.com
Study Finds GLP-1 Agonists Combined with Progestin Reduce Endometrial Cancer Risk by 66% geneonline.com
Endometriosis (EMT) and irritable bowel syndrome (IBS) disproportionately affect middle-aged and older women, where overlapping symptoms (e.g., chronic pelvic pain, bloating) and shared inflammatory mechanisms may drive comorbidity. However, large-scale …
Female reproductive disorders influence women's physical and mental well-being, and the sustainability of the family. However, it is unclear whether lifestyle factors, including sedentary behaviors and physical activity, could impact …
Professional societies recommend opportunistic salpingectomy during vaginal hysterectomy to reduce the risk of ovarian cancer, but it may be technically challenging without uterine prolapse. We examined national patterns, patient and …
Combining GLP-1 drugs with hormones may lower uterine cancer risk Medical Xpress